Human Insulin Market USD 32.8 Billion by 2020

According to a market research report Human Insulin Market 2013-2020 published by iHealthcareAnalyst, Inc., the global human insulin market is estimated to reach USD 32.8 Billion in 2020, expanding at a CAGR of 4.8% from 2016 to 2020.

Visit the Human Insulin Market 2013-2020 report at https://www.ihealthcareanalyst.com/report/insulin-market/

There are approximately 100 million people who need insulin around the world. This includes all people living with type 1 diabetes and between 20 to 30 percent of people with type 2 diabetes. The human insulin market can be broken into. The recombinant human segment is being displaced by the more effective but slightly more expensive insulin analogs.

The human insulin market report estimates the market size (Revenue USD million - 2013 to 2020) and composition of this market in terms of five product classes such as slow-acting, fast-acting, long-acting, intermediate-acting and premixed insulin and forecasts growth trends (CAGR% - 2016 to 2020). It also covers the major competitors operating in the market and provides a bird’s eye view of the different insulin analogs available in the global market.

The global human insulin market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

1. Source
1.1. Human
1.2. Recombinant

2. Mode of Action
2.1. Slow-Acting (Basal) Analogs
2.2. Fast-Acting Analogs
2.2.1. Pipeline Analysis
2.2.1.1. Afrezza
2.2.1.2. NN1218 (FIAsp)
2.3. Long-Acting Analogs
2.3.1. Pipeline Analysis
2.3.1.1. IDegLira (Xultophy)
2.3.1.2. LY2605541(Novel Basal Insulin Analog)
2.3.1.3. LY2963016 (Long Acting Basal Insulin)
2.3.1.4. MK-1293 (Sustained Release Insulin Analog)
2.3.1.5. U-300 (Toujeo)
2.4. Intermediate-Acting Analogs
2.5. Premixed Insulin

3. Company Profiles
3.1. Eli Lilly and Company
3.2. Novo Nordisk A/S
3.3. Sanofi
3.4. Thermalin Diabetes, LLC

1. Injection Type
1.1 Single-Injection Cycle
1.2 Three-Injection Cycle
1.3 Five- Injection Cycle

2. Applications
2.1 Osteoarthritis
2.2 Ophthalmic
2.3 Dermal Fillers
2.4 Vesicoureteral Reflux

3. Geography (Region, Country)
3.1 North America (U.S., Canada)
3.2 Latin America (Brazil, Mexico, Rest of LA)
3.3 Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4 Asia Pacific (Japan, China, India, Rest of APAC)
3.5 Rest of the World

4. Company Profiles
4.1 Alcon, Inc.
4.2 Allergan, Inc.
4.3 Anika Therapeutics, Inc.
4.4 F.Hoffmann-La Roche Ltd.
4.5 Ferring Pharmaceuticals, Inc.
4.6 Fidia Farmaceutici SpA
4.7 Galderma S.A.
4.8 Hyaltecg Ltd.
4.9 LifeCore Biomedical LLC
4.10 Meiji Seika Pharma Co. Ltd.
4.11 Merz Aesthetics, Inc.
4.12 Sanofi
4.13 Salix Pharmaceuticals, Inc.
4.14 Seikagaku Corporation
4.15 Shanghai Jingfeng Pharmaceutical Co. Ltd.
4.16 Smith & Nephew plc
4.17 TRB Chemedica International Sa
4.18 Zimmer Holdings, Inc.

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Ana Aitawa
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Phone: (314) 736-9294.
Email: sales@ihealthcareanalyst.com
https://www.ihealthcareanalyst.com

This release was published on openPR.